Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls. - Wikidata - awgldk - TriplyDB

Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls.

Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls.

http://www.wikidata.org/entity/Q34919885

about

Systems psychopharmacology: A network approach to developing novel therapies Etiology of cardiovascular disease in patients with schizophrenia: current perspectives An examination of the language construct in NIMH's research domain criteria: Time for reconceptualization!Common mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disorders Neuregulin-1 signalling and antipsychotic treatment: potential therapeutic targets in a schizophrenia candidate signalling pathway Expression of the neuregulin receptor ErbB4 in the brain of the rhesus monkey (Macaca mulatta)Investigation of gene effects and epistatic interactions between Akt1 and neuregulin 1 in the regulation of behavioral phenotypes and social functions in genetic mouse models of schizophrenia.Developmental vulnerability of synapses and circuits associated with neuropsychiatric disorders.Predictive suppression of cortical excitability and its deficit in schizophrenia.Increased expression of receptor phosphotyrosine phosphatase-β/ζ is associated with molecular, cellular, behavioral and cognitive schizophrenia phenotypes.What is the impact of genome-wide supported risk variants for schizophrenia and bipolar disorder on brain structure and function? A systematic review.Identification of SNP barcode biomarkers for genes associated with facial emotion perception using particle swarm optimization algorithm.Neuronal ablation of p-Akt at Ser473 leads to altered 5-HT1A/2A receptor function The DISC1 Ser704Cys substitution affects centrosomal localization of its binding partner PCM1 in glia in human brain Exonic DNA sequencing of ERBB4 in bipolar disorder Genetic variation in GAD1 is associated with cortical thickness in the parahippocampal gyrus.Common genetic variation in Neuregulin 3 (NRG3) influences risk for schizophrenia and impacts NRG3 expression in human brain.No association of ZNF804A rs1344706 with white matter integrity in schizophrenia: a tract-based spatial statistics study.MET and AKT genetic influence on facial emotion perception.Functional neuroimaging and schizophrenia: a view towards effective connectivity modeling and polygenic risk.Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions Intermediate phenotypes in psychiatric disorders.Variability in working memory performance explained by epistasis vs polygenic scores in the ZNF804A pathway.Lack of association to a NRG1 missense polymorphism in schizophrenia or bipolar disorder in a Costa Rican population ERBB4 polymorphism and family history of psychiatric disorders on age-related cortical changes in healthy children mTORC2/rictor signaling disrupts dopamine-dependent behaviors via defects in striatal dopamine neurotransmission.AKT/GSK3 signaling pathway and schizophrenia Convergent functional genomics of anxiety disorders: translational identification of genes, biomarkers, pathways and mechanisms.Schizophrenia: a pathogenetic autoimmune disease caused by viruses and pathogens and dependent on genes.Transgenic overexpression of the type I isoform of neuregulin 1 affects working memory and hippocampal oscillations but not long-term potentiation.Predicting white matter integrity from multiple common genetic variants.Schizophrenia candidate gene ERBB4: covert routes of vulnerability to psychosis detected at the population level Cumulative genetic risk and prefrontal activity in patients with schizophrenia.Neurological dysfunctions associated with altered BACE1-dependent Neuregulin-1 signaling.A common missense variant in the neuregulin 1 gene is associated with both schizophrenia and sudden cardiac death.Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.The effects of psychosis risk variants on brain connectivity: a review.Progress in imaging the effects of psychosis susceptibility gene variants.Neuroimaging as a potential biomarker to optimize psychiatric research and treatment.Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases

P2860

Q26750901-7D11DE73-D2EF-4CED-BFCF-AEEEB214D0CE Q26778485-5CF48ECC-7CE9-4E8A-89CF-7554F4E9CB92 Q28069268-CF6AA4F4-4F34-48C7-8CB5-B1224CD1A293 Q28086869-B6B5EAE1-3DFD-4D0A-B0E7-F32EEF3A303E Q28285114-E91BC6BE-87C6-46AF-86A5-8A0FE1AEF632 Q28743017-3ABCF3BD-B947-4C6D-AC0C-01ED62C78003 Q30418674-61258EA6-2B34-4DE1-A429-3CA9D3262FF7 Q30435763-E43ABE8E-6B7C-4076-A417-9B5299B6B062 Q30444541-36D5D9E6-2B97-46E8-8720-9CD162690744 Q30468818-F3A2B93E-CC04-442E-A2EC-16E46A3E61BF Q30928632-E85566D0-13AE-4E93-80AB-75C0EC4E4F50 Q33729161-1BBDEFBF-972C-4244-8846-A3E96C606C12 Q33814354-6C906B57-FFB8-4D79-85D4-7D899E8EF6D8 Q33878306-8CA577F0-7BC9-4EF2-A915-66E4DDA342C9 Q33921231-8C1A96E5-592E-41F9-A2E5-E2C06410AA63 Q33972445-CE794EDE-12A2-4BF5-9456-E08C0B14E524 Q34100294-4D0499B3-CF67-4F56-9A03-1F47E2F99FFA Q34132840-5DA464EE-6B63-40D4-A32A-86FEFE4DDEC2 Q34257203-D84BB4FD-60D6-4351-A010-A80F4007685F Q35029347-2543524D-B09A-41BC-AD90-3A2B91CD6D98 Q35049564-D115C901-71A4-4082-AC63-2083C3039C51 Q35112008-917AA425-B441-4811-AD6E-50462BF9FF22 Q35112316-F465F6DF-37AC-4AB7-8D9F-D591B6C201BF Q35175850-DA8F899A-A2D5-4210-9289-43B4FD0B0CF8 Q35249776-1C5FDC3B-353A-4024-9C68-2530665409F7 Q35707905-9B7C803F-C110-4E1A-BCD5-C8485695C602 Q35832061-DD0B1A89-14DD-4DBA-AE9F-F49453916E23 Q35844079-D18E1938-62CA-4271-8AF4-55B40E27C7A9 Q35909867-4CEFD5E6-0145-42AE-80FE-749A2E124056 Q36041415-72049104-3F6B-4C69-A2F6-E6446507AB43 Q36100330-4D0FD89D-D490-41C3-AFB3-FF6453C6EE67 Q36621060-DC3FA815-C139-4CAB-94A2-5979ED42AC6C Q36770072-50E4A654-35CE-4026-A115-BCEEE017D0B0 Q36804007-BBF2EA21-76BC-4ED4-9DC4-218CBAAD32B6 Q36954999-1B73177C-299B-476C-8634-0ED955BAD9CF Q37981491-91FB045B-0D90-4A32-BB7B-3963868A5909 Q37993528-E551BEB3-3D39-4920-BB79-1BABEA7FB5F2 Q38068612-25276480-9061-4371-ADDF-8723B9732F0D Q38154920-BB4366C5-CC5A-48CE-96BD-14B8B53CCA19 Q38225912-328B3A1B-B9E3-4FD8-A978-A8102893FC87

P2860

Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls.

http://www.wikidata.org/entity/Q34919885

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Biological validation of incre ...... roimaging in healthy controls.

@ast

Biological validation of incre ...... roimaging in healthy controls.

@en

Biological validation of incre ...... roimaging in healthy controls.

@nl

type

label

Biological validation of incre ...... roimaging in healthy controls.

@ast

Biological validation of incre ...... roimaging in healthy controls.

@en

Biological validation of incre ...... roimaging in healthy controls.

@nl

prefLabel

Biological validation of incre ...... roimaging in healthy controls.

@ast

Biological validation of incre ...... roimaging in healthy controls.

@en

Biological validation of incre ...... roimaging in healthy controls.

@nl

P1433

Q34919885-592CD071-00B2-434C-957A-636F0A1FAB47

P1476

Q34919885-619F9D4F-283C-4075-9540-A3877123D280

P2093

Q34919885-2833E7FD-4267-4265-AE77-D49830ACA54D

Q34919885-2E841CCA-23BB-4063-A31D-49732E31388D

Q34919885-4FCDEBCB-ECB2-43F6-AEDC-E8CA38929262

Q34919885-5B04B0BC-A091-4CD2-A024-C7F9A3A7EA6A

Q34919885-B9DCBC61-B17F-443B-8782-76FBD9BF1F63

Q34919885-D21F47F6-9BD4-4869-88CD-D2C0E00F192C

Q34919885-D552BD93-567D-44B0-B3DD-CBA5FA65E41B

Q34919885-F2553006-ACB9-4062-A8EA-5B4FB1655715

Q34919885-FB8D5379-567C-4B1C-8D64-83AE3FDCB6AC

P2860

Q34919885-0195C3A1-74A1-4F79-9EC8-871E7E22D3F8

Q34919885-04903318-5E39-4966-A1DD-6FF527FA3720

Q34919885-22B6BF60-DA39-4E3F-809F-F1B1C1F37579

Q34919885-242A7216-789E-49FB-86D1-F874E17854F9

Q34919885-2AF4183D-A546-441F-B877-7DB8199D57E4

Q34919885-2C268B96-2C9C-4B3B-ABF1-C3DF81F425EF

Q34919885-36396D38-CCEA-4FFB-AC36-62BDF43F505B

Q34919885-36D08A96-EBE1-4BBC-B33F-554DDA1B3D13

Q34919885-3AB5581C-3DB4-4912-A173-64BDC1B54BF5

Q34919885-3F9F237C-9536-400E-A184-8502AF9CB827

P304

Q34919885-3DA03538-9773-4158-AD8B-6F4779CD0773

P31

Q34919885-F072A2F1-7466-4E29-9814-A90924C01F48

P356

Q34919885-28DE734C-DFAD-4A7C-9AC4-36C391E99362

P407

Q34919885-5749A303-A750-44FD-BF1E-07C4B30C38FA

P433

Q34919885-81A2F8AE-57B9-4AF3-8B47-0788BB375A10

P478

Q34919885-7E84EE49-2432-4E47-B601-02A83F4B755A

P50

Q34919885-34018DD1-0995-411D-8393-60E3D10DDADE

Q34919885-5C5236E1-F199-4860-9A06-0583BF12B2BC

Q34919885-71E6BE22-FF22-4438-A243-A1398AB08A3B

Q34919885-A844BA25-4F2A-46EA-A922-47D448CDCDC5

Q34919885-F8831DDF-EDC2-475C-9A89-802FB7A09E28

Q34919885-FE82A091-3753-429A-B260-E172EB41CAB5

Q34919885-FFEBF3F9-D450-449E-821C-72A0E3444CA8

P577

Q34919885-17B021FE-BCFB-4735-B2D5-19481F037789

P5875

Q34919885-1E286661-4807-449D-96AB-0CB93C13BADC

P698

Q34919885-CFBA28BF-FA0B-41F5-B2E6-990BEFB9A3B1

P921

Q34919885-4E4CB34A-30C0-4C2F-BBD4-F9174514C107

Q34919885-ED751DCC-DF89-40E2-90B2-35B7B7F0E628

P932

Q34919885-270F7F07-8811-4A66-9D01-63F4CBCB355B

P356

ARCHGENPSYCHIATRY.2010.117

P1433

JAMA Psychiatry

P1476

Biological validation of incre ...... roimaging in healthy controls.

@en

P2093

Augustin Luna

http://www.w3.org/2001/XMLSchema#string

Bert Gold

http://www.w3.org/2001/XMLSchema#string

Eugenia Radulescu

http://www.w3.org/2001/XMLSchema#string

Hao-Yang Tan

http://www.w3.org/2001/XMLSchema#string

Kate McGee

http://www.w3.org/2001/XMLSchema#string

Kristin K Nicodemus

http://www.w3.org/2001/XMLSchema#string

Michael Dean

http://www.w3.org/2001/XMLSchema#string

Pierandrea Muglia

http://www.w3.org/2001/XMLSchema#string

Radhakrishna Vakkalanka

http://www.w3.org/2001/XMLSchema#string

P2860

Interactions among genes in the ErbB-Neuregulin signalling network are associated with increased susceptibility to schizophrenia

Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia

CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95

Genomewide linkage scan of 409 European-ancestry and African American families with schizophrenia: suggestive evidence of linkage at 8p23.3-p21.2 and 11p13.1-q14.1 in the combined sample.

Association of neuregulin 1 with schizophrenia confirmed in a Scottish population

Solution structure of the epidermal growth factor-like domain of heregulin-alpha, a ligand for p180erbB-4

Neuregulin 1 and susceptibility to schizophrenia.

Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia

Common polygenic variation contributes to risk of schizophrenia and bipolar disorder

Intermediate phenotypes and genetic mechanisms of psychiatric disorders

P304

991-1001

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHGENPSYCHIATRY.2010.117

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P50

Joseph H Callicott

Daniel R. Weinberger

Richard E Straub

Bhaskar Kolachana

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47336319

http://www.w3.org/2001/XMLSchema#string

P698

20921115

http://www.w3.org/2001/XMLSchema#string

P921

P932

4291187

http://www.w3.org/2001/XMLSchema#string